Home > Fixed 12 cycles and MRD-guided venetoclax consolidation is highly effective in CLL

Fixed 12 cycles and MRD-guided venetoclax consolidation is highly effective in CLL

Presented By
Dr Mark-David Levin, Albert Schweitzer Hospital, the Netherlands
Conference
EHA 2021
Trial
Phase 2, HOVON 139/GiVe
Primary endpoint results of the phase 2 HOVON 139/GiVe trial demonstrate high efficacy and good tolerability after fixed 12 cycles of venetoclax or minimal residual disease-guided treatment with venetoclax after pre-induction with obinutuzumab. These results warrant further study of both these treatment options for patients with naïve chronic lymphocytic leukaemia who were unfit for first-line fludarabine, cyclophosphamide, and rituximab. Fixed duration treatment of chronic lymphocytic leukaemia (CLL) patients with venetoclax combined with an anti-CD20 antibody results in high rates of undetectable minimal residual disease (uMRD) and prolonged progression-free survival (PFS) [1]. The next step in CLL treatment may be a tailored approach based on remission status. The randomised, phase 2 HOVON 139/GiVe trial included naïve CLL patients that were unfit for first-line fludarabine, cyclophosphamide, and rituximab and studied the impact of a standard or ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on